GMED logo

GLOBUS MEDICAL INC - A

GMEDNYSE
๐Ÿ† #637 by market capEarnings Nov 5US Equity
$85.15โ–ผ $0.99 (โˆ’1.16%)
๐ŸŒ™ After hours$86.87โ–ฒ 2.01%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ผ 1.2%
7dโ–ฒ 5.7%
14dโ–ฒ 4.8%
30dโ–ฒ 6.9%
1yโ–ฒ 37.6%
๐ŸฆMarket Cap
$11.56B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
+19.7%
Healthy
๐Ÿ“ŠGross Margin
68.5%
High
๐Ÿ’ตFCF Margin
23.9%
Strong
โš–๏ธP/S Ratio
3.5x
Fair
Otter Score
59
Weak

Trading Snapshot

Day Range
$83.80 โ€“ $86.75
52-Week Range
$54.15 โ€“ $101.40
Volume
$2.78B
Avg Volume
$3.69B
Shares Outstanding
135.7M
Next Earnings
Oct 13, 2026

Fundamentals Snapshot

Annual Revenue
$2.94B
Last Q Revenue
$790M
P/E Ratio
20.8
P/S Ratio
3.5x
EPS (TTM)
$3.91
Dividend Yield
โ€”

Why Investors Own GMED

  • โœ“High-growth profile โ€” revenue up +59.3% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 61% gross margin and 28% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.94Bโ–ฒ +62.5% YoY
Gross Margin (TTM)
61.2%โ–ฒ +4.3% YoY
Operating Income (TTM)
$326Mโ–ฒ +62.5% YoY
Free Cash Flow (TTM)
$811Mโ–ฒ +62.5% YoY

About GLOBUS MEDICAL INC - A

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
59/100

Analyst Ratings

โ“˜
Consensus
Buy
23 analysts
Strong Buy4
Buy12
Hold7
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

Yahooยท3d ago

Globus Medical Q2 Earnings Call Highlights

Globus Medical (NYSE:GMED) reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted

ChartMillยท3d ago

Globus Medical (NYSE:GMED): A Compelling Affordable Growth Opportunity

GMED earns top scores in growth, value, profitability & financial health, making it a standout pick in the Affordable Growth screen.

Yahooยท4d ago

GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution

Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.

๐Ÿš€
Benzingaยท4d ago

Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $99

Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $103 to $99.

Yahooยท4d ago

Globus Medical Inc (GMED) (Q2 2026) Earnings Call Highlights: Record EPS and Margin Expansion ...

Globus Medical Inc (GMED) delivers record Q2 EPS with 56% growth, while navigating Nevro stabilization and enabling tech transition.

ChartMillยท5d ago

Globus Medical (NYSE:GMED) Shares Rise on Q2 Earnings Beat and Raised Profit Guidance

Globus Medical beats Q2 earnings, raises FY profit guidance; revenue slightly misses but shares rise ~3% after hours.